This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Ages 18-70 years
High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc
Large B-cell lymphoma with a history of secondary CNS involvement
Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia
Cord blood as donor source in alloHCT
New York Heart Association Class III or IV
Left ventricular ejection fraction < 50%
Estimated glomerular filtration rate < 30 mL/min
Jonsson Comprehensive Cancer Center
Lead sponsor
AstraZeneca
Collaborator